US FDA approves Replimune's skin cancer drug

The U.S. Food and Drug Administration has approved ​Replimune's drug for a difficult-to-treat form ‌of skin cancer, the company said on Thursday, giving the biotech firm its first ​marketed product af...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。